Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...
The approval is based on results from a Phase 3 extension trial evaluating the efficacy and safety of Mirena. 2 “Now more than ever, it’s important to help ensure that women have the options they need ...
What options are available to treat irregular bleeding in women who are using the contraceptives etonogestrel (Implanon) or levonorgestrel (Mirena)?—GINA SAPP, ARNP, Perry, Fla. First, reassure her ...
Although the risk of acquiring PID at the time of insertion was not an issue for the woman presented in this case, historically she would not have been considered an appropriate candidate for an IUD.
The simplified insertion process is a milestone innovation for the market’s leading hormone-free contraceptive, with an efficacy rate greater than 99% 1,2 “Paragard has been a reliable contraceptive ...
The MarketWatch News Department was not involved in the creation of this content. ROSWELL, Ga., Oct. 15, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a leader in women's healthcare, announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback